| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.18 | 0.01 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.01 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.076 | 0.02 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |